Refining Management of Classical Hodgkin Lymphoma: What’s on the Horizon for Pediatric Management and AYA Survivorship

Target Audience
The educational design of this activity addresses the needs of community-based and academic/specialist hematologists, hematologic oncologists, medical oncologists, hematopathologists, primary care providers, family practitioner internists, hematology/oncology nurses and nurse navigators, nurse practitioners, physician assistants, and pharmacists.

Program Overview
New treatments are poised to expand the armamentarium for pediatric classical Hodgkin lymphoma (cHL). Given the high rate of long-term survival in the pediatric population, treatment selection should consider any anticipated late toxicities associated with therapy, as well as long-term follow-up and survivorship plans that effectively facilitate the transition from pediatric to young-adult care.

Join a panel of experts in hematology-oncology to discuss relevant treatment options for pediatric patients with cHL and individualization of treatment based on risk status and the latest guidelines. Panelists will review emerging treatment options in clinical trials and share strategies to monitor for treatment-related late effects and preserve quality of life during the transition from pediatric to adult care.

Learning Objectives
After completing this activity, the participant should be better able to:

Apply guideline- and evidence-based approaches to the management of patients with pediatric cHL
Discuss the rationale for new therapies and the clinical data supporting their utilization in the pediatric cHL population
Evaluate strategies to formulate long-term follow-up plans considering the transition from being a pediatric patient to adolescence and young adulthood